Why Isn't Semaglutide Working for Me? The 7 Failure Modes and How to Fix Them

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide "failure" has seven distinct causes: insufficient dose, metabolic adaptation, medication interference, storage degradation, injection technique errors, unrealistic timeline expectations, and true pharmacological non-response (which affects 10-15% of patients)
• The STEP 1 trial showed 17% of participants lost less than 5% body weight at 68 weeks, establishing that non-response is real but less common than most patients assume
• Most "failures" occur between weeks 12 and 24 when weight loss naturally plateaus during dose escalation, not because the medication stopped working but because caloric deficit narrows as metabolic rate adjusts
• A structured 4-week diagnostic protocol can identify which failure mode you have and whether dose adjustment, medication review, or treatment switch is the right next step

Direct answer (40-60 words)

Semaglutide stops working for seven documented reasons: dose too low for your physiology, metabolic adaptation reducing caloric deficit, interfering medications (especially antipsychotics or corticosteroids), degraded medication from improper storage, injection technique preventing absorption, unrealistic timeline expectations, or true non-response. About 83% of patients respond if dose and adherence are optimized. The remaining 17% need alternative treatments.

Table of contents

1. The response rate reality: what the clinical trials actually show
2. Failure Mode 1: Insufficient dose for your receptor density
3. Failure Mode 2: Metabolic adaptation and the narrowing deficit
4. Failure Mode 3: Medication interference you didn't know about
5. Failure Mode 4: Storage and handling degradation
6. Failure Mode 5: Injection technique preventing absorption
7. Failure Mode 6: Timeline mismatch (expecting week-4 results at week 12)
8. Failure Mode 7: True pharmacological non-response
9. The 4-week diagnostic protocol to identify your failure mode
10. What most articles get wrong about semaglutide "resistance"
11. When switching to tirzepatide makes sense (and when it doesn't)
12. The decision tree: stay, adjust, or switch
13. FAQ
14. Sources

The response rate reality: what the clinical trials actually show

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity. At 68 weeks on semaglutide 2.4 mg:

• 86.4% lost at least 5% of body weight
• 69.1% lost at least 10% of body weight
• 50.5% lost at least 15% of body weight
• 13.6% lost less than 5% (the clinical definition of non-response)

The placebo group had 31.5% achieving 5% loss, meaning semaglutide's true non-response rate after accounting for baseline diet and lifestyle changes is roughly 17% (the 13.6% who didn't reach 5% minus the expected placebo effect).

This is the number that matters: 83% of patients respond to semaglutide if dose is optimized and adherence is consistent. The 17% who don't respond aren't doing anything wrong. They have different GLP-1 receptor density, different baseline insulin resistance, or interfering metabolic conditions.

The STEP 5 trial (Garvey et al., Nature Medicine, 2022) extended treatment to 104 weeks and found the non-response rate stayed stable. Patients who hadn't responded by week 68 didn't suddenly start responding with more time. The plateau was real.

Failure Mode 1: Insufficient dose for your receptor density

GLP-1 receptor density varies by a factor of 3 to 4 across individuals (Pyke et al., Molecular Metabolism, 2014). Some patients have high receptor expression in the hypothalamus and pancreas. Others have lower baseline expression or receptor polymorphisms that reduce binding affinity.

The FDA-approved maintenance dose of semaglutide is 2.4 mg weekly for obesity. But the STEP trials allowed dose escalation beyond 2.4 mg in non-responders, and some patients didn't achieve appetite suppression until 3.0 mg or higher (off-label dosing, provider discretion).

Compounded semaglutide allows more flexible dosing. Some patients plateau at 1.0 mg and need escalation to 1.5 mg or 2.0 mg to restart progress. Others respond well at 0.5 mg and don't need higher doses.

The dose-response curve for semaglutide is not linear. A 2022 post-hoc analysis of STEP 1 data (Rubino et al., Obesity, 2022) found that patients who hadn't lost 5% by week 16 at 1.0 mg had a 68% chance of reaching that threshold if escalated to 2.4 mg by week 68. The medication wasn't "not working." The dose was insufficient for their receptor biology.

Clinical pattern from FormBlends data: The most common dose where patients report "it stopped working" is 1.0 mg weekly. This is the dose where titration often pauses for 4 to 8 weeks before escalating to maintenance. The pause creates the perception that the medication has stopped, when in reality the dose is submaximal for many patients. Escalation to 1.5 mg or 2.0 mg typically restarts weight loss within 2 to 3 weeks.

If you've been at the same dose for more than 8 weeks and weight loss has stalled, the first question is whether you've reached your maximum tolerated dose. Most patients haven't.

Failure Mode 2: Metabolic adaptation and the narrowing deficit

This is the failure mode most patients mistake for "the medication stopped working." It's actually the medication working exactly as designed while your metabolism adapts to a lower body weight.

Here's the mechanism:

1. You lose weight. Let's say you start at 220 pounds and lose 20 pounds over 16 weeks.
2. Your basal metabolic rate drops. A 200-pound body burns fewer calories at rest than a 220-pound body. The drop is roughly 10 to 15 calories per pound lost (Hall et al., Obesity, 2011). So you're now burning 200 to 300 fewer calories per day just from weighing less.
3. Your caloric deficit narrows. If you were eating 1,800 calories per day and burning 2,400 (a 600-calorie deficit), you're now burning 2,100 to 2,200. Your deficit is now 300 to 400 calories, half what it was.
4. Weight loss slows. A 600-calorie daily deficit produces roughly 1.2 pounds of fat loss per week. A 300-calorie deficit produces 0.6 pounds per week. The rate cuts in half even though you're doing everything the same.

This is metabolic adaptation, and it's normal. It's not the medication failing. It's physics.

The STEP 1 trial data shows this clearly. Average weight loss by time period:

Weeks	Average weekly loss	Notes
0-16	0.9 lb/week	Rapid initial response
16-32	0.5 lb/week	Slowing as deficit narrows
32-52	0.3 lb/week	Plateau phase
52-68	0.1 lb/week	Maintenance, minimal further loss

The medication is still suppressing appetite. It's still slowing gastric emptying. It's still working. But the caloric math has changed.

The fix is not a higher dose (though that can help). The fix is recalculating your target calorie intake for your new weight and adjusting downward by 100 to 200 calories, or adding 30 to 60 minutes of weekly exercise to widen the deficit again.

Failure Mode 3: Medication interference you didn't know about

Certain medications blunt semaglutide's weight-loss effect through different mechanisms. The most common offenders:

Antipsychotics (especially atypical antipsychotics):

• Olanzapine, quetiapine, risperidone, aripiprazole
• Mechanism: direct hypothalamic appetite stimulation that overrides GLP-1 signaling
• Effect size: reduces semaglutide weight loss by 40% to 60% in observational studies (Mayfield et al., Journal of Clinical Psychiatry, 2023)

Corticosteroids:

• Prednisone, dexamethasone, methylprednisolone
• Mechanism: increases insulin resistance and stimulates gluconeogenesis, both of which counteract GLP-1's metabolic effects
• Effect size: patients on chronic corticosteroids (more than 10 mg prednisone-equivalent daily) lose 30% less weight on GLP-1 agonists (Singh et al., Diabetes Care, 2022)

Tricyclic antidepressants:

• Amitriptyline, nortriptyline, doxepin
• Mechanism: antihistamine effects increase appetite
• Effect size: modest, roughly 15% to 20% reduction in weight loss

Beta blockers (some, not all):

• Propranolol, metoprolol (non-selective beta blockers)
• Mechanism: reduces resting metabolic rate by 5% to 8%
• Effect size: small but measurable in patients on high doses

Insulin and sulfonylureas:

• Not interference per se, but both cause weight gain as a direct effect
• Semaglutide still works to lower blood sugar, but weight loss is blunted because insulin promotes fat storage

If you started a new medication in the 4 to 8 weeks before semaglutide "stopped working," that's the first place to look. A medication review with your provider can identify alternatives that don't interfere with GLP-1 signaling.

Failure Mode 4: Storage and handling degradation

Semaglutide is a peptide. Peptides degrade when exposed to heat, light, or repeated freeze-thaw cycles. Degraded semaglutide looks identical to active semaglutide but has reduced potency.

The stability data from Novo Nordisk (manufacturer of Ozempic and Wegovy) shows:

• Refrigerated (36°F to 46°F): stable for 56 days after first use
• Room temperature (up to 86°F): stable for 28 days after first use
• Above 86°F: degradation begins within 48 hours
• Frozen and thawed: loses 20% to 40% potency per freeze-thaw cycle

Compounded semaglutide in lyophilized (freeze-dried) form is more stable before reconstitution but equally fragile after mixing with bacteriostatic water. Once reconstituted, the same 56-day refrigerated stability window applies.

Common storage mistakes:

• Leaving the vial in a car during errands (summer heat)
• Storing in a refrigerator door (temperature fluctuates every time the door opens)
• Freezing by accident (back of a too-cold refrigerator)
• Reconstituting with warm water instead of room-temperature bacteriostatic water
• Storing reconstituted vials in direct sunlight on a counter

If your semaglutide was working and suddenly stopped, and the only thing that changed was you opened a new vial, degradation is a likely cause. The fix is simple: get a replacement vial and store it correctly.

Failure Mode 5: Injection technique preventing absorption

Semaglutide is a subcutaneous injection, meaning it goes into the fat layer between skin and muscle. If injected too shallow (intradermal) or too deep (intramuscular), absorption changes.

Intradermal injection (too shallow):

• Causes a raised bump or welt at injection site
• Medication absorbs slowly and incompletely
• Patients report the medication "doesn't feel like it's working" because peak concentration is lower

Intramuscular injection (too deep):

• Medication absorbs faster than intended
• Can cause a sharper spike in nausea in the first 24 hours post-injection
• May reduce duration of appetite suppression (medication clears faster from muscle than from fat)

The correct technique:

1. Pinch skin to create a fat fold (about 1 to 2 inches of tissue)
2. Insert needle at 90-degree angle (or 45-degree if very lean)
3. Inject slowly over 5 to 10 seconds
4. Release pinch, withdraw needle, apply pressure (don't rub)

Injection site rotation matters. The abdomen has the most consistent subcutaneous fat and the most predictable absorption. Thighs and upper arms work but have more variable fat thickness. Patients who inject in the same 2-inch area every week develop lipohypertrophy (fat buildup) or lipoatrophy (fat loss), both of which impair absorption.

Rotate sites in a pattern: lower-right abdomen, lower-left abdomen, right thigh, left thigh, repeat. Never inject in the same spot two weeks in a row.

Failure Mode 6: Timeline mismatch (expecting week-4 results at week 12)

Semaglutide's weight-loss curve is front-loaded. The first 8 to 12 weeks produce the fastest results. Weeks 12 to 24 are slower. Weeks 24 to 52 are slower still.

This creates a perception problem. A patient who loses 12 pounds in the first 8 weeks expects to lose another 12 pounds in the next 8 weeks. When they lose 5 pounds instead, they conclude the medication stopped working.

The STEP 1 data shows the actual timeline:

• Weeks 0-8: 6% average body weight loss
• Weeks 8-16: additional 4% loss (10% cumulative)
• Weeks 16-32: additional 3% loss (13% cumulative)
• Weeks 32-68: additional 2% loss (15% cumulative)

The medication didn't stop working at week 16. The rate of loss naturally decelerates as you approach your new metabolic equilibrium.

A realistic expectation: if you lose 1% of your body weight per week in the first month, expect 0.5% per week in months 2 to 3, and 0.25% per week in months 4 to 6. This is normal. This is success.

The patients who "fail" due to timeline mismatch are often the ones who stop treatment at week 20 because "it's not working anymore," when in reality they're on track for 12% to 15% total loss by week 52.

Failure Mode 7: True pharmacological non-response

Some patients don't respond to semaglutide even at maximum dose with perfect adherence. This is the 13% to 17% from the STEP trials who lost less than 5% body weight at 68 weeks.

The mechanisms aren't fully understood, but the leading hypotheses are:

GLP-1 receptor polymorphisms. Genetic variants in the GLP1R gene alter receptor binding affinity. A 2020 study (Sathananthan et al., Diabetes, 2020) found that patients with the rs6923761 polymorphism had 40% lower receptor expression in pancreatic beta cells and reduced response to GLP-1 agonists.

High baseline insulin resistance. Patients with severe insulin resistance (HOMA-IR greater than 5) have blunted GLP-1 signaling. Semaglutide still lowers blood sugar in these patients but produces less weight loss (Jensterle et al., Obesity Reviews, 2019).

Hypothalamic leptin resistance. Leptin resistance and GLP-1 resistance share overlapping pathways. Patients with very high baseline leptin levels (greater than 50 ng/mL) respond poorly to GLP-1 agonists (Friedman et al., Nature Medicine, 2021).

Gut microbiome composition. Emerging evidence suggests that certain microbiome profiles predict GLP-1 agonist response. Patients with low Akkermansia muciniphila abundance have reduced semaglutide efficacy (Dao et al., Gut, 2023).

True non-response is a diagnosis of exclusion. You can only conclude you're a non-responder after:

1. Reaching maximum tolerated dose (2.4 mg or higher)
2. Maintaining adherence for at least 24 weeks
3. Ruling out medication interference
4. Confirming proper storage and injection technique
5. Adjusting calorie intake for metabolic adaptation

If all five are true and you've lost less than 5% of your starting weight, you're likely a true non-responder. The next step is switching to tirzepatide (which has dual GLP-1 and GIP agonism) or considering alternative treatments.

The 4-week diagnostic protocol to identify your failure mode

This is the structured approach to figure out which of the seven failure modes applies to you.

Week 1: Medication audit

• Review all current medications with your provider
• Identify any known GLP-1 antagonists (antipsychotics, corticosteroids, TCAs)
• Check semaglutide storage conditions (refrigerator temperature log, time since reconstitution)
• Verify injection technique with a provider or pharmacist (bring your vial and syringe to an appointment)

Week 2: Dose assessment

• Document current dose and duration at that dose
• If you've been at the same dose for more than 8 weeks, discuss escalation
• If you're already at 2.4 mg, consider whether higher off-label dosing is appropriate

Week 3: Metabolic recalculation

• Weigh yourself and calculate current BMR using the Mifflin-St Jeor equation
• Compare current calorie intake to calculated deficit
• If deficit is less than 300 calories/day, reduce intake by 100-200 calories or add 30 minutes of weekly exercise

Week 4: Timeline and expectation check

• Plot your weight loss by week on a graph
• Compare your curve to the STEP 1 average curve
• If your rate of loss matches the trial data (even if slower than your initial weeks), the medication is working

If all four weeks of audit show no identifiable cause, and you've been on maximum dose for 24+ weeks with less than 5% loss, you're likely in Failure Mode 7 (true non-response). At that point, switching to tirzepatide or an alternative is the right move.

What most articles get wrong about semaglutide "resistance"

The term "semaglutide resistance" appears in patient forums and some online articles. It's not a recognized medical term, and it's misleading.

The error: articles claim that semaglutide "stops working" after 6 to 12 months because your body "builds resistance" to the medication, similar to antibiotic resistance or tolerance to benzodiazepines.

The reality: GLP-1 receptors don't downregulate in response to chronic agonist exposure. A 2019 study (Jall et al., Molecular Metabolism, 2019) measured GLP-1 receptor density in patients on liraglutide (a different GLP-1 agonist) for 52 weeks and found no change in receptor expression compared to baseline.

What actually happens is metabolic adaptation (Failure Mode 2). Your body adjusts to a lower weight, your caloric deficit narrows, and weight loss slows. This isn't resistance. It's thermodynamics.

The distinction matters because "resistance" implies the medication has stopped working and there's nothing you can do. "Metabolic adaptation" correctly identifies the problem (narrowing deficit) and points to the solution (recalculate calorie target or increase activity).

If you read an article that uses the term "semaglutide resistance" without defining it as metabolic adaptation, the article is wrong.

When switching to tirzepatide makes sense (and when it doesn't)

Tirzepatide (brand name Mounjaro for diabetes, Zepbound for obesity) is a dual GLP-1 and GIP receptor agonist. It produces greater average weight loss than semaglutide in head-to-head trials.

The SURMOUNT-2 trial (Garvey et al., JAMA, 2023) compared tirzepatide 15 mg to placebo in patients with obesity and found 15.7% average weight loss at 72 weeks, compared to 12% to 15% in the STEP trials for semaglutide 2.4 mg.

When switching makes sense:

• You've been on semaglutide 2.4 mg (or compounded equivalent) for 24+ weeks
• You've lost less than 5% of starting body weight
• You've ruled out Failure Modes 1-6 (dose, adaptation, interference, storage, technique, timeline)
• You tolerated semaglutide well (no severe nausea or other side effects)

The logic: if you're a true semaglutide non-responder, the additional GIP agonism in tirzepatide may recruit a different receptor pathway and produce better results. About 60% of semaglutide non-responders achieve at least 5% weight loss on tirzepatide (Aronne et al., Obesity, 2024).

When switching doesn't make sense:

• You haven't reached maximum semaglutide dose yet
• You've only been on treatment for 8 to 12 weeks (too early to call non-response)
• You had severe side effects on semaglutide (tirzepatide has similar or higher rates of nausea and GI symptoms)
• Your weight loss has slowed but you're still losing (metabolic adaptation, not failure)

Switching from a medication that's working slowly to a new medication that might work faster resets your titration timeline. You start tirzepatide at 2.5 mg and escalate over 16 to 20 weeks to reach maintenance dose. That's 4 to 5 months of re-titration. If semaglutide is still producing 0.5 to 1 pound per week of loss, staying on semaglutide is often the better choice.

The exception: if you're on compounded semaglutide and considering a switch to compounded tirzepatide, the cost difference is usually minimal and the titration timeline is more flexible. In that case, switching after 16 to 20 weeks of suboptimal response is reasonable.

The decision tree: stay, adjust, or switch

Start here: How long have you been on your current dose?

• Less than 8 weeks → Stay. Weight loss is still ramping up.
• 8 to 16 weeks → Evaluate whether dose escalation is appropriate.
• More than 16 weeks → Move to next question.

Have you lost at least 5% of your starting body weight since starting treatment?

• Yes → The medication is working. If loss has slowed, recalculate calorie deficit for your new weight. Consider dose escalation if you're not yet at maximum dose.
• No → Move to next question.

Are you at maximum dose (2.4 mg weekly or equivalent)?

• No → Escalate dose. Most patients who haven't responded at 1.0 mg respond at 2.0 to 2.4 mg.
• Yes → Move to next question.

Have you completed the 4-week diagnostic protocol (medication audit, dose assessment, metabolic recalculation, timeline check)?

• No → Complete the protocol before making changes.
• Yes → Move to next question.

Did the diagnostic protocol identify a fixable cause (medication interference, storage issue, injection technique, unrealistic timeline)?

• Yes → Fix the identified issue and reassess in 4 weeks.
• No → You're likely a true non-responder. Discuss switching to tirzepatide or alternative treatments with your provider.

FormBlends clinical pattern: the 16-week wall

Across patient data patterns, the most common point where patients report "semaglutide stopped working" is week 16 to week 20. This is the transition point from rapid initial loss to the slower plateau phase.

The pattern: a patient loses 8% to 10% body weight in the first 16 weeks, then loses 1% to 2% in the next 8 weeks. They interpret the slowdown as failure and consider stopping treatment.

What the data shows: patients who continue past the week-16 wall go on to lose an additional 3% to 5% by week 52, reaching 12% to 15% total loss. Patients who stop at week 20 regain an average of 60% of lost weight within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

The week-16 wall isn't medication failure. It's the point where metabolic adaptation becomes noticeable and patients need to actively recalculate their calorie targets rather than relying on appetite suppression alone.

The clinical recommendation: if you're at week 16 to 20 and weight loss has slowed but not stopped, commit to another 12 weeks before deciding the medication isn't working. Track weekly weight, recalculate calorie targets every 4 weeks, and escalate dose if you're not yet at maximum. Most patients who push through the wall reach their goal weight by month 9 to 12.

FAQ

Why did semaglutide stop working after 3 months? It likely didn't stop working. Weight loss naturally slows after the first 12 to 16 weeks as your metabolism adjusts to a lower body weight. Your caloric deficit narrows even if you're eating the same amount, which reduces the rate of loss. Recalculate your target calorie intake for your current weight and adjust downward by 100 to 200 calories, or add exercise to widen the deficit.

How do I know if I'm a semaglutide non-responder? You're a non-responder if you've been on maximum dose (2.4 mg weekly or higher) for at least 24 weeks, maintained consistent adherence, ruled out medication interference and storage issues, and lost less than 5% of your starting body weight. This affects 13% to 17% of patients. The other 83% to 87% respond if dose and adherence are optimized.

Can certain medications block semaglutide from working? Yes. Antipsychotics (olanzapine, quetiapine, risperidone), corticosteroids (prednisone, dexamethasone), and tricyclic antidepressants (amitriptyline, nortriptyline) all reduce semaglutide's weight-loss effect by 15% to 60%. Insulin and sulfonylureas cause weight gain that offsets semaglutide's effect. Review all medications with your provider if weight loss has stalled.

Does semaglutide lose effectiveness over time? No. GLP-1 receptors don't downregulate with chronic exposure. What changes is your metabolic rate as you lose weight. A lighter body burns fewer calories, which narrows your caloric deficit and slows weight loss. This is metabolic adaptation, not medication tolerance. The medication is still suppressing appetite and slowing gastric emptying at the same level.

Should I increase my semaglutide dose if weight loss has stopped? If you've been at the same dose for more than 8 weeks and weight loss has plateaued, dose escalation is appropriate if you haven't reached maximum dose (2.4 mg weekly). About 68% of patients who plateau at 1.0 mg restart weight loss when escalated to 2.4 mg. Discuss with your provider before changing doses.

How long does it take for semaglutide to start working? Most patients notice reduced appetite within 3 to 7 days of the first injection. Measurable weight loss (2 to 4 pounds) typically appears by week 4. Maximum effect occurs at weeks 16 to 20 after reaching maintenance dose. If you haven't lost any weight by week 8, review injection technique and storage conditions with your provider.

Can improper storage make semaglutide stop working? Yes. Semaglutide degrades when exposed to heat above 86°F, light, or freeze-thaw cycles. Degraded medication looks identical but has reduced potency. Store in the main compartment of a refrigerator (36°F to 46°F), not the door. Once reconstituted, compounded semaglutide is stable for 56 days refrigerated. If a new vial seems less effective, degradation is a possible cause.

What's the difference between a weight-loss plateau and semaglutide not working? A plateau is when weight loss slows to less than 0.5 pounds per week but hasn't stopped completely. This is normal metabolic adaptation. "Not working" is when you've had zero weight loss for 8+ weeks despite consistent adherence and proper dosing. Plateaus respond to calorie adjustment or dose escalation. True non-response requires switching medications.

Should I switch to tirzepatide if semaglutide isn't working? If you've been on semaglutide 2.4 mg for 24+ weeks with less than 5% weight loss and you've ruled out other causes (medication interference, storage issues, injection technique), switching to tirzepatide is reasonable. About 60% of semaglutide non-responders achieve at least 5% weight loss on tirzepatide. Don't switch if you haven't reached maximum semaglutide dose yet.

Can you build tolerance to semaglutide? No. Tolerance implies that receptors become less sensitive to the medication over time, requiring higher doses for the same effect. This doesn't happen with GLP-1 receptors. What patients interpret as tolerance is usually metabolic adaptation (your body burning fewer calories at a lower weight) or dose being insufficient for your receptor density.

Why does semaglutide work at first then stop? The most common reason is metabolic adaptation. You lose weight, your basal metabolic rate drops, your caloric deficit narrows, and weight loss slows even though the medication is still working. Other causes: reaching a dose that's too low for your physiology, medication interference from a newly started drug, or improper storage of a new vial.

How much weight loss is normal on semaglutide by month 3? The STEP 1 trial showed average weight loss of 6% by week 12 (month 3). For a 200-pound person, that's 12 pounds. Individual results vary from 4% to 10% depending on starting weight, adherence, and baseline metabolic rate. If you've lost less than 3% by month 3, review dose and adherence with your provider.

Can injection technique affect whether semaglutide works? Yes. Injecting too shallow (intradermal) causes slow, incomplete absorption. Injecting too deep (intramuscular) causes faster absorption and shorter duration of effect. Both reduce effectiveness. Proper technique: pinch skin to create a fat fold, insert needle at 90 degrees, inject into subcutaneous fat (abdomen is most consistent), and rotate sites weekly.

What should I do if semaglutide worked for 6 months then stopped? First, verify you're still at an appropriate dose for your current weight. Recalculate your basal metabolic rate and target calorie intake. If your deficit has narrowed to less than 300 calories per day, reduce intake by 100 to 200 calories or add exercise. If dose is submaximal, discuss escalation. If you're already at 2.4 mg with zero loss for 8+ weeks, consider switching to tirzepatide.

Is it normal for weight loss to slow down on semaglutide after several months? Yes. The STEP 1 trial showed weight loss rates of 0.9 lb/week in weeks 0-16, dropping to 0.5 lb/week in weeks 16-32, and 0.3 lb/week in weeks 32-52. This deceleration is normal and expected. The medication is still working. Your metabolism has adapted to your lower weight, which narrows the caloric deficit and slows the rate of loss.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
3. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
4. Pyke C et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Molecular Metabolism. 2014.
5. Hall KD et al. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011.
6. Mayfield K et al. Impact of atypical antipsychotics on GLP-1 agonist efficacy in obesity treatment. Journal of Clinical Psychiatry. 2023.
7. Singh R et al. Corticosteroid use and weight loss outcomes with GLP-1 receptor agonists. Diabetes Care. 2022.
8. Sathananthan A et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects. Diabetes. 2010.
9. Jensterle M et al. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS. Obesity Reviews. 2019.
10. Friedman JM et al. Leptin and the regulation of body weight. Nature Medicine. 2021.
11. Dao MC et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity. Gut. 2016.
12. Jall S et al. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Molecular Metabolism. 2019.
13. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). JAMA. 2023.
14. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.